TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02009423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03482908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early healthy lifestyles
Description: Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive parenting curriculum
Description: Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data sharing/coordination
Description: Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
Study: NCT03418142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priovi
Description: Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAU
Description: Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
Study: NCT03237052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model
Description: a model that has been established in advance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-model
Description: real-world psychiatrist decision
Study: NCT03162328

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PowerSleep Stim
Description: Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerSleep Stim
Description: Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PowerSleep Sham
Description: Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerSleep Sham
Description: Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
Study: NCT02574936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A new surgical technique
Description: Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used
Study: NCT04901832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic stretching exercises
Description: Exercises performed actively and passively to reduce or prevent muscle cramps during hemodialysis procedure.
Study: NCT03898700

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: strength based coaching
Description: strength based and solution focused coaching
Study: NCT02555553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-GSH with Noom Monitor
Description: This intervention is cognitive behavioral treatment with a smartphone application
Study: NCT04433299

Intervention type: OTHER
Intervention: no intervention, observational
Description: no intervention, observational

Intervention type: OTHER
Intervention: no intervention, observational
Description: no intervention, observational
Study: NCT03718377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia only
Description: Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
Study: NCT02185105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A MTO
Description: Randomized to a test lens in one eye and control lens in the other as a matched pair.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Randomized to a test lens in one eye and control lens in the other as a matched pair.
Study: NCT05436405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb
Description: Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases.
Study: NCT00971997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro Mix 50/50
Description: Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
Study: NCT02850549

Intervention type: OTHER
Group type: OTHER
Intervention: Procedure: physical therapy and Neck Pain Classification
Description: Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
Study: NCT03708497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid plus misoprostol
Description: 1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
Study: NCT04601324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Participants will be required to use fluticasone propionate nasal spray twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine hydrochloride and fluticasone propionate
Description: Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: Rupatadine once daily for a total of 2 weeks.
Study: NCT01306539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation of the subthalamic nucleus
Description: Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
Study: NCT04520568

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: using sedation with the HFNC F\&P AIRVOTM 2 to maintain oxygenation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: using general anaesthesia with one lung ventilation (OLV) technique
Study: NCT03430544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Oral Capsule [Vraylar]
Description: Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Oral Capsule [Vraylar]
Description: Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
Study: NCT04592094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blueback® Physio
Description: Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
Study: NCT04682782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
Study: NCT00384605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule once daily. Treatment for 52 weeks.
Study: NCT01535651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program with Media Enhancement (TOP4ME)
Description: Persons participating in TOP will receive text messages weekly in addition to TOP
Study: NCT00560157

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crucial (enteral tube feeding)
Description: Evaluation of new enteral product, Crucial, in ICU patients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crucial (enteral tube feeding)
Description: Evaluation of new enteral product, Crucial, in ICU patients
Study: NCT00953147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 80 mcg
Description: Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 160 mcg
Description: Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
Study: NCT03145012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
Study: NCT03317847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09 % Ophthalmic Solution
Description: Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% ophthalmic suspension
Description: Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
Study: NCT01226732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.
Study: NCT03604705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: APX001
Study: NCT01226732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
Study: NCT02578849

Intervention type: DRUG
Intervention: L-DOPA
Description: Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.

Intervention type: DRUG
Intervention: L-DOPA
Description: Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.

Intervention type: DRUG
Intervention: L-DOPA
Description: Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
Study: NCT02707900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7).
Study: NCT01956760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and intradermal acupuncture
Description: The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
Study: NCT00552890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: subjects assigned to follow modified Atkins diet for 1 year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADA recommended diet
Description: subjects assigned to follow ADA recommended diet for period of 1 year
Study: NCT01226732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AUY 922
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
Study: NCT00064649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Microwave Thermotherapy (TUMT)
Description: type of minimally invasive surgical therapy for BPH

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Needle Ablation (TUNA) Therapy
Description: type of minimally invasive surgical therapy for BPH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride and Alfuzosin
Description: finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
Study: NCT02594449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzalkonium Chloride Solution
Description: To compare pharmacodynamics among the different concentrations of BCS and NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Chloride Solution
Description: To compare pharmacodynamics among the different concentrations of BCS and NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Chloride Solution
Description: To compare pharmacodynamics among the different concentrations of BCS and NS
Study: NCT04387877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston
Description: Graston technique will be applied on the lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~For the first 2 weeks; dorsolumbar stabilization, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham graston technique will be applied on lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied by partially touching the skin overlying the muscle or fascia region via ultrasound gel with the flat part of the Graston instrument so as not to provide any activity of the fascia) For the first 2 weeks; dorsolumbar stabilization, counting on spot, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises